TPL2 kinase regulates the inflammatory milieu of the myeloma niche

Blood

Volumn 123, Issue 21, 2014, Pages 3305-3315

  Hope, Chelsea ^a,b   Ollar, Samuel J ^a,b   Heninger, Erika ^b   Hebron, Ellen ^a,b   Jensen, Jeffrey L ^a,b   Kim, Jaehyup ^a,b   Maroulakou, Ioanna ^c   Miyamoto, Shigeki ^b,d   Leith, Catherine ^a   Yang, David T ^a   Callander, Natalie ^a,b   Hematti, Peiman ^a,b   Chesi, Marta ^e   Bergsagel, P Leif ^e   Asimakopoulos, Fotis ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PHOSPHOTRANSFERASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROGRESSION LOCUS 2 KINASE; UNCLASSIFIED DRUG; VERSICAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL GROWTH; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE LOSS; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VIVO STUDY; INFLAMMATION; LATENT PERIOD; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; REPOLARIZATION; STROMA CELL; TUMOR MICROENVIRONMENT;

ANIMALS; CYTOKINES; DRUG DISCOVERY; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-1BETA; MACROPHAGES; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6; TUMOR MICROENVIRONMENT;

EID: 84903177242     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-554071     Document Type: Article

References (101)

1. Lohr JG, Stojanov P, Carter SL, et al Multiple Myeloma Research Consortium. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91-101.
2. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467-472.
3. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
4. Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120(5):1060-1066.
5. Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067-1076.
6. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28(2):384-390.
7. Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res. 2011;17(6):1243-1252.
8. Kyle RA, Buadi F, Rajkumar SV. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park). 2011;25(7):578-586.
9. Melchor L, Brioli A, Wardell CP, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma [published online ahead of print January 13, 2014]. Leukemia. doi: 10.1038/leu.2014.13.
10. Landgren O, Morgan GJ. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice. Clin Cancer Res. 2014;20(4):804-813.
11. Anderson KC, Lust JA. Role of cytokines in multiple myeloma. Semin Hematol. 1999;36(1 Suppl 3):14-20. (Pubitemid 29081128)
12. Ehrlich LA, Roodman GD. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunol Rev. 2005;208:252-266. (Pubitemid 41746397)
13. Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003;78(2):106-113. (Pubitemid 37021949)
14. Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer. 2003;97(10):2440-2452. (Pubitemid 36542483)
15. Klein B, Seckinger A, Moehler T, Hose D. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. Recent Results Cancer Res. 2011;183:39-86.
16. Otsuki T, Yata K, Sakaguchi H, et al. IL-10 in myeloma cells. Leuk Lymphoma. 2002;43(5):969-974. (Pubitemid 34460878)
17. Klein B, Lu ZY, Gu ZJ, Costes V, Jourdan M, Rossi JF. Interleukin-10 and Gp130 cytokines in human multiple myeloma. Leuk Lymphoma. 1999;34(1-2):63-70. (Pubitemid 29248660)
18. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am. 1999;13(6):1117-1125. (Pubitemid 30017389)
19. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw. 1999;10(1):65-70. (Pubitemid 29158740)
20. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
21. Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012;2012:157496.
22. Durie BG, Vela EE, Frutiger Y. Macrophages as an important source of paracrine IL6 in myeloma bone marrow. Curr Top Microbiol Immunol. 1990;166:33-36.
23. Hebron E, Hope C, Kim J, et al. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol. 2013;160(6):779-784.
24. Kim J, Denu RA, Dollar BA, et al. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol. 2012;158(3):336-346.
25. Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114(17):3625-3628.
26. Ribatti D, Vacca A. The role of monocytes-macrophages in vasculogenesis in multiple myeloma. Leukemia. 2009;23(9):1535-1536.
27. Asimakopoulos F, Kim J, Denu RA, et al. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma. 2013;54(10):2112-2121.
28. Ribatti D, Moschetta M, Vacca A. Macrophages in multiple myeloma [published online ahead of print December 24, 2013]. Immunol Lett. doi: 10.1016/j.imlet.2013.12.010.
29. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol. 2001;166(1):249-255. (Pubitemid 32038439)
30. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135-145. (Pubitemid 33741967)
31. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev. 2009;227(1):221-233.
32. Kim S, Takahashi H, Lin WW, et al. Carcinomaproduced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009; 457(7225):102-106.
33. Said N, Sanchez-Carbayo M, Smith SC, Theodorescu D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest. 2012;122(4):1503-1518.
34. Du WW, Yang BB, Shatseva TA, et al. Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS ONE. 2010;5(11):e13828.
35. Gao D, Joshi N, Choi H, et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012;72(6):1384-1394.
36. Du WW, Yang W, Yee AJ. Roles of versican in cancer biology - tumorigenesis, progression and metastasis. Histol Histopathol. 2013;28(6):701-713.
37. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 2012;72(19):4883-4889.
38. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 2009;28(1-2):233-245.
39. Vougioukalaki M, Kanellis DC, Gkouskou K, Eliopoulos AG. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett. 2011;304(2):80-89.
40. Gantke T, Sriskantharajah S, Ley SC. Regulation and function of TPL-2, an IkB kinase-regulated MAP kinase kinase kinase. Cell Res. 2011;21(1):131-145.
41. Dumitru CD, Ceci JD, Tsatsanis C, et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell. 2000;103(7):1071-1083. (Pubitemid 32040907)
42. Yang DT, Quann PJ, Petrich AM, Leith CP, Young KH, Kahl BS. Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma. Appl Immunohistochem Mol Morphol. 2011;19(1):62-69.
43. Oberley MJ, Rajguru SA, Zhang C, et al. Immunohistochemical evaluation of MYC expression in mantle cell lymphoma. Histopathology. 2013;63(4):499-508.
44. López-Pelaéz M, Fumagalli S, Sanz C, et al. Cot/tpl2-MKK1/2-Erk1/2 controls mTORC1-mediated mRNA translation in Toll-like receptoractivated macrophages. Mol Biol Cell. 2012;23(15):2982-2992.
45. Anderson P. Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat Rev Immunol. 2010;10(1):24-35.
46. Hao S, Baltimore D. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat Immunol. 2009;10(3):281-288.
47. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol. 2009;37(12):1445-1453.
48. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
49. Ozinsky A, Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A. 2000;97(25):13766-13771.
50. Li D, Wang X, Wu JL, et al. Tumor-produced versican V1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression in vitro. PLoS ONE. 2013;8(2):e56616.
51. Wight TN, Kinsella MG, Evanko SP, Potter-Perigo S, Merrilees MJ. Versican and the regulation of cell phenotype in disease [published online ahead of print January 5, 2014]. Biochim Biophys Acta. doi: 10.1016/j.bbagen.2013.12.028.
52. Stanton H, Melrose J, Little CB, Fosang AJ. Proteoglycan degradation by the ADAMTS family of proteinases. Biochim Biophys Acta. 2011;1812(12):1616-1629.
53. McCulloch DR, Nelson CM, Dixon LJ, et al. ADAMTS metalloproteases generate active versican fragments that regulate interdigital web regression. Dev Cell. 2009;17(5):687-698.
54. Formato M, Farina M, Spirito R, et al. Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler Thromb Vasc Biol. 2004;24(1):129-135. (Pubitemid 38082423)
55. Brown HM, Dunning KR, Robker RL, et al. ADAMTS1 cleavage of versican mediates essential structural remodeling of the ovarian follicle and cumulus-oocyte matrix during ovulation in mice. Biol Reprod. 2010;83(4):549-557.
56. Bret C, Hose D, Reme T, et al. Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment. Exp Hematol. 2011;39(5):546-557.E548.
57. Mielke LA, Elkins KL, Wei L, et al. Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J Immunol. 2009;183(12):7984-7993.
58. Chesi M, Matthews GM, Garbitt VM, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood. 2012;120(2):376-385.
59. Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167-180. (Pubitemid 351163163)
60. Patriotis C, Makris A, Bear SE, Tsichlis PN. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A. 1993;90(6):2251-2255. (Pubitemid 23078604)
61. Serebrennikova OB, Tsatsanis C, Mao C, et al. Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation. Proc Natl Acad Sci U S A. 2012;109(18):E1082-E1091.
62. Kim G, Khanal P, Kim JY, et al. COT phosphorylates prolyl-isomerase Pin1 to promote tumorigenesis in breast cancer [published online ahead of print November 22, 2013]. Mol Carcinog. doi: 10.1002/mc.22112.
63. Decicco-Skinner KL, Jung SA, Tabib T, et al. Tpl2 knockout keratinocytes have increased biomarkers for invasion and metastasis. Carcinogenesis. 2013;34(12):2789-2798.
64. Lee WJ, Lan KH, Chou CT, et al. Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination. Neoplasia. 2013;15(9):1036-1048.
65. Lee HW, Joo KM, Lim JE, et al. Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma. Mol Cancer Res. 2013;11(11):1375-1386.
66. Gkirtzimanaki K, Gkouskou KK, Oleksiewicz U, et al. TPL2 kinase is a suppressor of lung carcinogenesis. Proc Natl Acad Sci U S A. 2013;110(16):E1470-E1479.
67. Tunca B, Tezcan G, Cecener G, et al. Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients. J Cancer Res Clin Oncol. 2013;139(4):691-702.
68. Koliaraki V, Roulis M, Kollias G. Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis. J Clin Invest. 2012;122(11):4231-4242.
69. Fernández M, Manso R, Bernaldo de Quirós F, López P, Martín-Duce A, Alemany S. Involvement of Cot activity in the proliferation of ALCL lymphoma cells [published correction appears in Biochem Biophys Res Commun. 2012;421(1):157]. Biochem Biophys Res Commun. 2011;411(4):655-660.
70. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968- 972.
71. Wang X, Gocek E, Novik V, Harrison JS, Danilenko M, Studzinski GP. Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3). Cell Cycle. 2010;9(22):4542-4551.
72. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1beta-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2):114-122.
73. Breslin WL, Strohacker K, Carpenter KC, Haviland DL, McFarlin BK. Mouse blood monocytes: Standardizing their identification and analysis using CD115. J Immunol Methods. 2013;390(1-2):1-8.
74. Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 2012;26(12):2538-2545.
75. Martinez FO. Regulators of macrophage activation. Eur J Immunol. 2011;41(6):1531-1534.
76. Ploeger DT, Hosper NA, Schipper M, Koerts JA, de Rond S, Bank RA. Cell plasticity in wound healing: paracrine factors of M1/M2 polarized macrophages influence the phenotypical state of dermal fibroblasts. Cell Commun Signal. 2013;11(1):29.
77. López-Peláez M, Soria-Castro I, Boscá L, Fernández M, Alemany S. Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: Implications for NO synthase 2 expression. Eur J Immunol. 2011;41(6):1733-1741.
78. Porta C, Rimoldi M, Raes G, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A. 2009;106(35):14978-14983.
79. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol. 2008;180(4):2011-2017.
80. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461-466. (Pubitemid 39329586)
81. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokinedriven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121(7):977-990. (Pubitemid 40884391)
82. Hagemann T, Lawrence T, McNeish I, et al. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008;205(6):1261-1268. (Pubitemid 351831483)
83. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood. 2009;113(14):3139-3146.
84. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335-348.
85. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333-339.
86. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-510.
87. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175-187. (Pubitemid 37328787)
88. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011;8(8):479-491.
89. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87(1):78-88.
90. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood. 1991;77(12):2794-2795.
91. Suematsu S, Matsusaka T, Matsuda T, et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1992;89(1):232-235.
92. Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;161(3):357-366.
93. Mitsiades CS, McMillin DW, Klippel S, et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007;21(6):1007-1034, vii-viii. (Pubitemid 350051349)
94. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70(Suppl 1):i104-i108.
95. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM. 1997;90(1):19-25. (Pubitemid 27075848)
96. Pavlova EV, Wang SZ, Archer J, et al. B cell lymphoma and myeloma in murine Gaucher's disease. J Pathol. 2013;231(1):88-97.
97. Xiong Y, Donovan KA, Kline MP, et al. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res. 2006;26(2):83-95. (Pubitemid 43364045)
98. Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol. 1998;103(4):1152-1160. (Pubitemid 29012658)
99. Abdi J, Mutis T, Garssen J, Redegeld F. Characterization of the Toll-like receptor expression profile in human multiple myeloma cells. PLoS ONE. 2013;8(4):e60671.
100. Ricciardelli C, Frewin KM, Tan IA, et al. The ADAMTS1 protease gene is required for mammary tumor growth and metastasis. Am J Pathol. 2011;179(6):3075-3085.
101. Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011;19(1):31-44.